Anticancer photodynamic and non-photodynamic effects of pterin derivatives on a pancreatic cancer cell line

Journal of Pharmacological Sciences

Volumn 107, Issue 2, 2008, Pages 221-225

  Miyoshi, Takashi ^a   Arai, Toshiyuki ^a   Nonogawa, Mitsuru ^b   Makino, Keisuke ^b   Mori, Hiroko ^c   Yamashita, Kouhei ^a   Sasada, Masataka ^b  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Higashiyama Takeda Hospital   (Japan)

Author keywords

Anticancer drug; Photodynamic effect; Pterin derivative

Indexed keywords

2 (N,N DIMETHYLAMINOMETHYLENEAMINO) 3 PIVALOYLPTERIDIN 4 ONE; 2 (N,N DIMETHYLAMINOMETHYLENEAMINO) 6 FORMYL 3 PIVALOYLPTERIDIN 4 ONE; ANTINEOPLASTIC AGENT; PTERIN DERIVATIVE; WATER;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; PANCREAS CANCER; PHOTODYNAMICS; ULTRAVIOLET A RADIATION;

EID: 46449129334     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08002SC     Document Type: Article

References (15)

1. Lowry OH, Bessey OA, Crawford EJ. Pterine oxidase. J Biol Chem. 1949;180:399-410.
2. Kalckar HM, Kjeldgaard NO, Klenow H. 2-Amino-4-hydroxy-6-formylpteridine, an inhibitor of purine and pterine oxidases. Biochim Biophys Acta. 1950;5:586-594.
3. Halpern R, Halpern BC, Stea B, Dunlap A, Conklin K, Clark B, et al. Pterin-6-aldehyde, a cancer cell catabolite: identification and application in diagnosis and treatment of human cancer. Proc Natl Acad Sci U S A. 1977;74:587-591.
4. Arai T, Endo N, Yamashita K, Sasada M, Mori H, Ishii H, et al. 6-formylpterin, a xanthine oxidase inhibitor, intracellularly generates reactive oxygen species involved in apoptosis and cell proliferation. Free Radic Biol Med. 2001;30:248-259.
5. Thomas AH, Lorente C, Capparelli AL, Martinez CG, Braun AM, Oliveros E. Singlet oxygen (1deltag) production by pterin derivatives in aqueous solutions. Photochem Photobiol Sci. 2003;2:245-250.
6. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889-905.
7. Pervaiz S. Reactive oxygen-dependent production of novel photochemotherapeutic agents. Faseb J. 2001;15:612-617.
8. Nonogawa M, Arai T, Endo N, Pack SP, Kodaki T, Makino K. Novel 6-formylpterin derivatives: chemical synthesis and O2 to ROS conversion activities. Org Biomol Chem. 2006;4:1811-1816.
9. Yamada H, Arai T, Endo N, Yamashita K, Nonogawa M, Makino K, et al. Photodynamic effects of a novel pterin derivative on a pancreatic cancer cell line. Biochem Biophys Res Commun. 2005;333:763-767.
10. Nonogawa M, Pack SP, Arai T, Endo N, Sommani P, Kodaki T, et al. Reactive oxygen species generation through NADH oxidation by 6-formylpterin derivatives in the dark. Biochem Biophys Res Commun. 2007;353:1105-1110.
11. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
12. Petrat F, Pindiur S, Kirsch M, de Groot H. NAD(P)H, a primary target of 1O2 in mitochondria of intact cells. J Biol Chem. 2003;278:3298-3307.
13. Royall JA, Ischiropoulos H. Evaluation of 2′,7′- dichlorofluorescin and dihydrorhodamine 123 as fluorescent probes for intracellular H2O2 in cultured endothelial cells. Arch Biochem Biophys. 1993;302:348-355.
14. Bollimuntha S, Singh BB, Shavali S, Sharma SK, Ebadi M. TRPC1-mediated inhibition of 1-methyl-4-phenylpyridinium ion neurotoxicity in human SH-SY5Y neuroblastoma cells. J Biol Chem. 2005;280:2132-2140.
15. Scaduto RC Jr, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J. 1999;76:469-477.